Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Gilead and Eisai Submitted an Application to Japan’s PMDA for Approval of Filgotinib for UC

April 23, 2021 0

Gilead Sciences and Eisai Pharmaceutical Co Submitted an Application to Japan's PMDA for Filgotinib Galapagos NV …

Bristol-Myers Squibb: CHMP of the EMA Recommended Additional Approval of Onureg® as Maintenance Therapy for AML

April 23, 2021 0

European Authorities Recommended Additional Approval of Bristol-Myers Squibb Product Onureg® for AML Bristol-Myers Squibb (BMY): The …

Humanigen Inc Product Lenzilumab Combination with CAR T in DLBCL Protects from Severe Cytokine Syndrome

April 21, 2021 0

Humanigen Product Lenzilumab Combination with CAR-T At the recommended Phase 2 dose, lenzilumab in combination with …

Cassava Sciences Guidance for Simufilam. See Also: Its First Quarter 2021 Financial Results

April 21, 2021 0

Cassava Sciences Guidance and Financial Results Cassava Sciences (SAVA) announced financial results for the first quarter …

Vir Biotechnology and GlaxoSmithKline: The European Medicines Agency Started a Review of VIR-7831 for COVID-19

April 20, 2021 0

Vir Biotechnology and GlaxoSmithKline in April 2020 In April 2020, Vir Biotechnology and GlaxoSmithKline entered into …

Amylyx Pharmaceuticals: Continuing to Offer Promising Results in Treating ALS

April 20, 2021 0

Amylyx Pharmaceuticals Updated Plans to Advance AMX0035 Amylyx Pharmaceuticals, Inc. provided an update on its plans …

CureVac N.V.

April 18, 2021 0

Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about …

Inovio DNA Vaccine Candidate INO-4800 has Promising Results. Read Also: Sutro Biopharma Good News

April 15, 2021 0

Inovio Pharmaceuticals Promising Results for INO-4800 for COVID-19 Inovio Pharmaceuticals (INO) announces promising results of a …

Gilead Sciences: Another Accelerated Cancer Approval from the FDA

April 14, 2021 0

FDA Grants Accelerated Approval for Gilead Sciences Trodelvy® The United States Food and Drug Administration (FDA) …

The FDA Granted Breakthrough Therapy Designation to vTv Therapeutics for Type 1 Diabetes Product TTP399

April 13, 2021 0

vTv Therapeutics Receives Breakthrough Therapy Designation for TTP399 vTv Therapeutics (VTVT) - a clinical-stage biopharmaceutical company …

Re-Working Some Evaluated Biotechnology Firms

April 11, 2021 0

Prohost Portfolio PLUS #2 Re-Working Some Evaluated Biotechnology Firms Exelixis: 2020 and 2021 Wondering why Exelixis’ …

Gilead Sciences: FDA Fully Approves Trodelvy for Metastatic TNBC

April 8, 2021 0

Gilead Sciences is Granted FDA Approval for Trodelvy® Gilead Sciences (GILD), a company that has been …

Exelixis Latest News. See Also: TransMedics Group May Improve on Heart Transplants

April 7, 2021 0

Exelixis Latest News The latest news announced by Exelixis (EXEL) is the FDA acceptance of its …

Intellia Therapeutics Announces More Good News

April 5, 2021 0

Intellia Therapeutics NTLA-2001 for ATTR Granted Orphan Drug Designation by the EC Intellia Therapeutics (NTLA) announced …

Exelixis CABOMETYX: Now Approved in Europe for First-Line Treatment of Renal Cell Carcinoma

April 1, 2021 0

Exelixis Boxed in on Good News Exelixis (EXEL) is one of the firms boxed in by …

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN’s Stock Price

March 31, 2021 0

Illumina Acquisition of GRAIL On September 21, 2020, Illumina and GRAIL Inc. announced that they entered into …

A Biotech Firm We Love to Discover

March 30, 2021 0

Rubius Therapeutics Finding small development-stage biotech firms that contribute to biotechnology's limitless revolution of the biological …

Your Questions, Our Answers

March 28, 2021 2

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues …

Intellia Therapeutics’ Important Current Presentations

March 25, 2021 0

Current Presentations from Intellia Therapeutics Intellia Therapeutics (NTLA) is presenting the first preclinical data set on …

Novartis Announced Positive Results of Phase 3 Study Using 177Lu-PSMA-617 in Advanced Prostate Cancer Patients

March 24, 2021 0

Novartis Positive Results for Radioligand Therapy, 177Lu-PSMA-617, for mCRPC Novartis (NVS) reported the first interpretable results …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Gilead and Eisai Submitted an Application to Japan’s PMDA for Approval of Filgotinib for UC

Bristol-Myers Squibb: CHMP of the EMA Recommended Additional Approval of Onureg® as Maintenance Therapy for AML

Humanigen Inc Product Lenzilumab Combination with CAR T in DLBCL Protects from Severe Cytokine Syndrome

Cassava Sciences Guidance for Simufilam. See Also: Its First Quarter 2021 Financial Results

Vir Biotechnology and GlaxoSmithKline: The European Medicines Agency Started a Review of VIR-7831 for COVID-19

Amylyx Pharmaceuticals: Continuing to Offer Promising Results in Treating ALS

CureVac N.V.

Inovio DNA Vaccine Candidate INO-4800 has Promising Results. Read Also: Sutro Biopharma Good News

Gilead Sciences: Another Accelerated Cancer Approval from the FDA

The FDA Granted Breakthrough Therapy Designation to vTv Therapeutics for Type 1 Diabetes Product TTP399

Re-Working Some Evaluated Biotechnology Firms

Gilead Sciences: FDA Fully Approves Trodelvy for Metastatic TNBC

Exelixis Latest News. See Also: TransMedics Group May Improve on Heart Transplants

Intellia Therapeutics Announces More Good News

Exelixis CABOMETYX: Now Approved in Europe for First-Line Treatment of Renal Cell Carcinoma

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN’s Stock Price

A Biotech Firm We Love to Discover

Your Questions, Our Answers

Intellia Therapeutics’ Important Current Presentations

Novartis Announced Positive Results of Phase 3 Study Using 177Lu-PSMA-617 in Advanced Prostate Cancer Patients